Business Context and Reporting Period
MIRA Pharmaceuticals, Inc. (MIRA), a Florida-based emerging growth company, filed this Form 8-K on June 17, 2025. The report details significant scientific and operational milestones regarding its lead drug candidate, Ketamir-2, and its broader clinical pipeline.
Key Financial Metrics
This filing is an "Other Events" report (Item 8.01) and does not contain financial statements. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Operational Updates
- Scientific Publication: The article "KETAMIR-2, A NEW MOLECULAR ENTITY AND NOVEL KETAMINE ANALOG" has been accepted for publication in Frontiers in Pharmacology. Authored by Chief Scientific Advisor Dr. Itzchak Angel, the paper validates Ketamir-2's pharmacological profile.
- Ketamir-2 Clinical Progress: The ongoing Phase 1 clinical trial for neuropathic pain is advancing as planned with dose escalation underway and no reported safety concerns. A Phase 2a trial is expected to initiate by year-end 2025, pending regulatory clearance.
- Acquisition Status: The acquisition of SKNY Pharmaceuticals, which includes the obesity and smoking cessation candidate SKNY-1, is progressing on track. Required regulatory filings for the merger have been submitted to the SEC.
Outlook, Risks, and Management Commentary
Management highlights the scientific validation of Ketamir-2 as a differentiated oral alternative to traditional ketamine. Key attributes noted include selective, low-affinity NMDA antagonism, no significant off-target activity across 40+ CNS receptors, and no hyperlocomotion in preclinical models. The company plans additional data submissions and presentations throughout 2025. No specific financial risks or contingencies were detailed in this filing.
Investor Verification Checklist
- Verify the publication status of the Ketamir-2 article in Frontiers in Pharmacology.
- Monitor the initiation date of the Phase 2a trial for neuropathic pain (target: year-end 2025).
- Track the regulatory approval status of the SKNY Pharmaceuticals merger.
- Review upcoming quarterly reports for financial metrics not included in this 8-K.